Docetaxel plus 5-fluorouracil and cisplatin (DCF) induction chemotherapy for locally advanced borderline-resectable T4 esophageal cancer

Anticancer Research

Volumn 31, Issue 10, 2011, Pages 3535-3541

  Yokota, Tomoya ^a   Hatooka, Shunzo ^a   Ura, Takashi ^a   Abe, Tetsuya ^a   Takahari, Daisuke ^a   Shitara, Kohei ^a   Nomura, Motoo ^a   Kondo, Chihiro ^a   Mizota, Ayako ^a   Yatabe, Yasushi ^a   Shinoda, Masayuki ^a   Muro, Kei ^a  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

5 fluorouracil; Borderline resectable T4; Cisplatin; DCF; Docetaxel; Esophageal cancer; Induction chemotherapy

Indexed keywords

CISPLATIN; DOCETAXEL; FLUOROURACIL;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BLEEDING; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CHYLOTHORAX; CLINICAL ARTICLE; CONTINUOUS INFUSION; DIARRHEA; DRUG EFFICACY; ESOPHAGUS CANCER; ESOPHAGUS RESECTION; FEBRILE NEUTROPENIA; FEMALE; HUMAN; INFECTION; KIDNEY INFECTION; LARYNGEAL NERVE; LEUKOPENIA; LUNG EMBOLISM; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NERVE PARALYSIS; NEUTROPENIA; PNEUMONIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SUBCUTANEOUS EMPHYSEMA; THROMBOCYTOPENIA; TREATMENT OUTCOME; TREATMENT RESPONSE; VEIN EMBOLISM; VOMITING; WOUND INFECTION;

AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; DISEASE-FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM STAGING; POSTOPERATIVE COMPLICATIONS; RECURRENCE; RETROSPECTIVE STUDIES; TAXOIDS; TREATMENT OUTCOME;

EID: 80054726318     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Fujita H, Kakegawa T, Yamana H, Shima I, Toh Y, Tomita Y, Fujii T, Yamasaki K, Higaki K and Noake T: Mortality and morbidity rates, postoperative course, quality of life and prognosis after extended radical lymphadenectomy for esophageal cancer. Ann Surg 222: 654-662, 1995.
2. Kato H, Watanabe H, Tachimori and Y, Iizuka T: Evaluation of neck lymph node dissection for thoracic esophageal carcinoma. Ann Thorac Surg 51: 931-935, 1991.
3. Igaki H, Kato H, Ando N, Shinoda M, Shimizu H, Nakamura T, Ozawa S, Yabusaki H, Aoyama N, Kurita A and Fukuda H: A randomized trial of postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus neoadjuvant chemotherapy for clinical stage II/III squamous cell carcinoma of the thoracic esophagus (JCOG 9907). J Clin Oncol 26(suppl): 215s, abstr 4510, 2008.
4. Ohtsu A, Boku N, Muro K, Chin K, Muto M, Yoshida S, Satake M, Ishikura S, Ogino T, Miyata Y, Seki S, Kaneko K and Nakamura A: Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus. J Clin Oncol 17: 2915-2921, 1999. (Pubitemid 29415253)
5. Mariette C, Piessen G, Lamblin A, Mirabel X, Adenis A and Triboulet JP: Impact of preoperative radiochemotherapy on postoperative course and survival in patients with locally advanced squamous cell oesophageal carcinoma. Br J Surg 93: 1077-1083, 2006. (Pubitemid 44343504)
6. Bedenne L, Michel P, Bouché O, Milan C, Mariette C, Conroy T, Pezet D, Roullet B, Seitz JF, Herr JP, Paillot B, Arveux P, Bonnetain F and Binquet C: Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol 25: 1160-1168, 2007. (Pubitemid 46640561)
7. Posner MR, Hershock DM, Blajman CR, Mickiewicz E, Winquist E, Gorbounova V, Tjulandin S, Shin DM, Cullen K, Ervin TJ, Murphy BA, Raez LE, Cohen RB, Spaulding M, Tishler RB, Roth B, Viroglio Rdel C, Venkatesan V, Romanov I, Agarwala S, Harter KW, Dugan M, Cmelak A, Markoe AM,Read PW, Steinbrenner L, Colevas AD, Norris CM Jr, Haddad RI; TAX 324 Study Group: Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer. N Engl J Med 357: 1705-1715, 2007. (Pubitemid 350005152)
8. Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, Stewart JS, Jelic S, Betka J, Preiss JH, van den Weyngaert D, Awada A, Cupissol D, Kienzer HR, Rey A, Desaunois I, Bernier J, Lefebvre JL; EORTC 24971/TAX 323 Study Group: Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 357: 1695-1704, 2007.
9. Ajani JA, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Marabotti C, Van Cutsem E; V-325 Study Group: Clinical benefit with docetaxel plus fluorouracil and cisplatin compared with cisplatin and fluorouracil in a phase III trial of advanced gastric or gastroesophageal cancer adenocarcinoma: the V-325 Study Group. J Clin Oncol 25: 3205-3209, 2007. (Pubitemid 47333732)
10. Tanaka Y, Yoshida K, Sanada Y, Osada S, Yamaguchi K and Takahashi T: Biweekly docetaxel, cisplatin, and 5-fluorouracil (DCF) chemotherapy for advanced esophageal squamous cell carcinoma: a phase I dose-escalation study. Cancer Chemother Pharmacol 66: 1159-1165, 2010.
11. Sobin LH and Wittedkind CH: UICC TNM Classification of Malignant Tumors, 6th edition. New York: Wiley-Liss, Inc., pp. 60-64, 2002.
12. Ura T, Nagase M, Fujii H, Hironaka S, Hatooka S, Hosoya Y, Yokota T, Shitara K, Takahari D, Muro K and Shinoda M: Feasibility study of preoperative docetaxel (D), cisplatin (C), and fluorouracil (F) in esophageal cancer. ASCO Gastrointestinal Cancers Symposium, abstr 81, 2010.
13. Isono K: Guidelines for Clinical and Pathologic Studies on Carcinoma of the Esophagus, ninth edition: Preface, general principles, part I. Esophagus 1: 61-88, 2004.
14. Japanese Society for Esophageal Diseases: Guidelines for Clinical and Pathologic Studies on Carcinoma of the Esophagus, ninth edition: Preface, general principles, part II. Esophagus 1: 107-125, 2004.
15. Siewert JR, Stein HJ, Feith M, Braecher BL, Bartels H and Fink U: Histologic tumor type is an independent prognostic parameter in esophageal cancer: Lessons from more than 1,000 consecutive resections at a single center in the Western world. Ann Surg 234: 360-369, 2001. (Pubitemid 32847073)
16. Gebski V, Burmeister B, Smithers BM, Foo K, Zalcberg J and Simes J: Australasian Gastro-Intestinal Trials Group: Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: a meta-analysis. Lancet Oncol 8: 226-234, 2007. (Pubitemid 46291702)
17. Stahl M, Stuschke M, Lehmann N, Meyer HJ, Walz MK, Seeber S, Klump B, Budach W, Teichmann R, Schmitt M, Schmitt G, Franke C and Wilke H: Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 23: 2310-2317, 2005. (Pubitemid 46218723)
18. Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N and Hennessy TP: A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med 335: 462-467, 1996. (Pubitemid 26269945)
19. Urba SG, Orringer MB, Turrisi A, Iannettoni M, Forastiere A and Strawderman M: Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol 19: 305-313, 2001. (Pubitemid 32112841)
20. Burmeister BH, Smithers BM, Gebski V, Fitzgerald L, Simes RJ, Devitt P, Ackland S, Gotley DC, Joseph D, Millar J, North J, Walpole ET and Denham JW; Trans-Tasman Radiation Oncology Group; Australasian Gastro-Intestinal Trials Group: Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol 6: 659-668, 2005. (Pubitemid 41222756)
21. Bosset JF, Gignoux M, Triboulet JP, Tiret E, Mantion G, Elias D, Lozach P, Ollier JC, Pavy JJ, Mercier M and Sahmoud T: Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus. N Engl J Med 337: 161-167, 1997. (Pubitemid 27306287)
22. Lee JL, Park SI, Kim SB, Jung HY, Lee GH, Kim JH, Song HY, Cho KJ, Kim WK, Lee JS, Kim SH and Min YI: A single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for resectable esophageal squamous cell carcinoma. Ann Oncol 15: 947-954, 2004. (Pubitemid 39004352)
23. Ishida K, Ando N, Yamamoto S, Ide H and Shinoda M: Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group trial (JCOG9516). Jpn J Clin Oncol 54: 615-619, 2004. (Pubitemid 40662717)
24. Ishikura S, Ohtsu A, Shirao K, Muro K, Kagami Y, Nihei K, Mera K, Ito Y, Boku N and Yoshida S: A phase I/II study of nedaplatin and 5-fluorouracil with concurrent radiotherapy in patients with T4 esophageal cancer: Japan Clinical Oncology Group trial (JCOG 9908). Esophagus 2: 133-137, 2005. (Pubitemid 41374033)
25. Medical Research Council Oesophageal Cancer Working Group: Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet 359: 1727-1733, 2002.
26. Meredith KL, Weber JM, Turaga KK, Siegel EM, McLoughlin J, Hoffe S, Marcovalerio M, Shah N, Kelley S and Karl R: Pathologic response after neoadjuvant therapy is the major determinant of survival in patients with esophageal cancer. Ann Surg Oncol 17: 1159-1167, 2010.